Acinetobacter News and Research

RSS
Tackling superbugs with antibiotic resistance breakers: an interview with Professor Colin Garner, Chief Executive, Antibiotic Research UK

Tackling superbugs with antibiotic resistance breakers: an interview with Professor Colin Garner, Chief Executive, Antibiotic Research UK

Novel method uses light-activated nanodrug to help fight antibiotic-resistant infections

Novel method uses light-activated nanodrug to help fight antibiotic-resistant infections

Anti-biofilm compounds show promise against drug-resistant bacteria associated with hospital-acquired infections

Anti-biofilm compounds show promise against drug-resistant bacteria associated with hospital-acquired infections

Naturally occurring clay exhibits potent antibacterial activity against ESKAPE pathogens

Naturally occurring clay exhibits potent antibacterial activity against ESKAPE pathogens

Carbapenem-resistant Enterobacteriaceae: an interview with Dr. Michael Dudley

Carbapenem-resistant Enterobacteriaceae: an interview with Dr. Michael Dudley

Antivirulence antibiotics could evade resistance longer than traditional antibiotics

Antivirulence antibiotics could evade resistance longer than traditional antibiotics

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

Cleaning patient rooms with combination of chemicals and UV light cuts transmission of superbugs

Cleaning patient rooms with combination of chemicals and UV light cuts transmission of superbugs

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Multidrug-resistant bacteria can naturally relinquish its ability to resist antibiotics

Multidrug-resistant bacteria can naturally relinquish its ability to resist antibiotics

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

NYU researchers identify root cause of eye infections among contact lens wearers

NYU researchers identify root cause of eye infections among contact lens wearers

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

NIAID funds nine research projects to advance rapid diagnostics tests for drug-resistant bacteria

NIAID funds nine research projects to advance rapid diagnostics tests for drug-resistant bacteria

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia